Evidence map›Paper›PMID 34789266›Full record

ArticleJournal of nanobiotechnology2021

Engineered extracellular vesicles derived from primary M2 macrophages with anti-inflammatory and neuroprotective properties for the treatment of spinal cord injury.

Chuanjie Zhang, Daoyong Li, Hengshuo Hu, Zhe Wang, Jinyu An, Zhanshan Gao, Kaihua Zhang, Xifan Mei, Chao Wu, He Tian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Chuanjie ZhangDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121002, Liaoning, China.
Daoyong LiDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121002, Liaoning, China.
Hengshuo HuDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121002, Liaoning, China.
Zhe WangDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121002, Liaoning, China.
Jinyu AnPharmacy School, Jinzhou Medical University, No. 40, Songpo Road, Jinzhou, 121002, Liaoning, China.
Zhanshan GaoPharmacy School, Jinzhou Medical University, No. 40, Songpo Road, Jinzhou, 121002, Liaoning, China.
Kaihua ZhangDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121002, Liaoning, China.
Xifan MeiDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121002, Liaoning, China. meixifan@jzmu.edu.cn.ORCID http://orcid.org/0000-0003-3698-0525
Chao WuPharmacy School, Jinzhou Medical University, No. 40, Songpo Road, Jinzhou, 121002, Liaoning, China. wuchao@jzmu.edu.cn.
He TianDepartment of Histology and Embryology, Jinzhou Medical University, No. 40, Songpo Road, Jinzhou, 121002, Liaoning, China. tianhe@jzmu.edu.cn.
Jinzhou Medical University · CN

Funding

national natural science foundation of china 81871556national natural science foundation of china 82072165national natural science foundation of china no. 81671907program for liaoning innovative talents in university no. XLYC1902108
6 · The paper itself

Abstract

backgroundUncontrollable inflammation and nerve cell apoptosis are the most destructive pathological response after spinal cord injury (SCI). So, inflammation suppression combined with neuroprotection is one of the most promising strategies to treat SCI. Engineered extracellular vesicles with anti-inflammatory and neuroprotective properties are promising candidates for implementing these strategies for the treatment of SCI.

resultsBy combining nerve growth factor (NGF) and curcumin (Cur), we prepared stable engineered extracellular vesicles of approximately 120 nm from primary M2 macrophages with anti-inflammatory and neuroprotective properties (Cur@EVs

conclusionsA series of in vivo and in vitro experiments showed that the engineered extracellular vesicles significantly improved the microenvironment after injury and promoted the recovery of motor function after SCI. We provide a new method for inflammation suppression combined with neuroprotective strategies to treat SCI.

Indexed as

Anti-Inflammatory AgentsNeuroprotective AgentsAnimalsBiocompatible MaterialsCurcuminExtracellular VesiclesMacrophagesMaleMiceMice, Inbred C57BLNeuroprotectionSpinal Cord InjuriesAnti-Inflammatory AgentsBiocompatible MaterialsCurcuminNeuroprotective AgentsCurcuminExtracellular vesiclesM2 repolarizationNeuroprotectionSpinal cord injury

Identifiers

PMID34789266
PMCPMC8600922
OpenAlexW3212072386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.